The US Food and Drug Administration has approved Neurocrine Biosciences’ drug to treat a type of genetic disorder, the health regulator’s website showed. The drug will be used along with glucocorticoids, a type of steroid, to control androgen levels in adults and paediatric patients aged 4 years and older with classic congenital adrenal hyperplasia.